ReviewNeuro-oncology practice2025
Who will benefit from vorasidenib? Review of data from the literature and open questions.
Amélie Darlix et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this papercites it
ReviewNeuro-oncology practice2025
Amélie Darlix et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.